You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Dementia Risk Associated With Benzodiazepine Use

  • Authors: News Author: Megan Brooks
    CME Author: Hien T. Nghiem, MD
  • CME/CE Released: 10/11/2012; Reviewed and Renewed: 11/6/2012
  • Valid for credit through: 10/11/2013, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This article is intended for primary care clinicians, pharmacists, psychiatrists, neurologists, and any other specialist who cares for patients with dementia.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Report the uses of benzodiazepines.
  2. Assess the association between benzodiazepines and risk for subsequent dementia.


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Megan Brooks

    Megan Brooks is a freelance writer for Medscape Medical News.


    Disclosure: Megan Brooks has no relevant financial relationships to disclose.


  • Brande Nicole Martin, MA

    CME Clinical Editor, Medscape, LLC


    Disclosure: Brande Nicole Martin, MA, has disclosed no relevant financial relationships.

CME Author(s)

  • Hien T. Nghiem, MD

    Hien T. Nghiem, MD, is a freelance writer for Medscape.


    Disclosure: Hien T. Nghiem, MD, has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Sarah Fleischman

    CME Program Manager, Medscape, LLC


    Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This enduring material activity, Medscape Education Clinical Briefs has been reviewed and is acceptable for up to 260 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2012. Term of approval is for 1 year from this date. Each Clinical Brief is approved for .25 Prescribed credits. Credit may be claimed for 1 year from the date of each Clinical Brief. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Note: Total credit is subject to change based on topic selection and article length.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    AAFP Accreditation Questions

    Contact This Provider

    For Pharmacists

  • Medscape, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number 0461-0000-12-135-H01-P)

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Dementia Risk Associated With Benzodiazepine Use

Authors: News Author: Megan Brooks CME Author: Hien T. Nghiem, MDFaculty and Disclosures

CME/CE Released: 10/11/2012; Reviewed and Renewed: 11/6/2012

Valid for credit through: 10/11/2013, 11:59 PM EST


Clinical Context

Benzodiazepines are indicated for treating anxiety and sleep disorders for a short period of time; however, benzodiazepine use is often chronic. It is not uncommon for people age 65 years and older to take benzodiazepines. The long-term adverse effects of benzodiazepines are not clearly understood, especially in relation to risk for dementia.

The aim of this study by Billioti de Gage and colleagues is to evaluate the association between use of benzodiazepines and incident dementia.

Study Synopsis and Perspective

Older adults who use benzodiazepines have about a 50% greater chance of developing dementia than their peers who don't use benzodiazepines, French researchers observed in a large population-based study.

This finding, added to evidence of increased risk for falls and fractures in elderly who use benzodiazepine, "should incite (health providers) to carefully assess expected benefits versus putative risks, and to limit prescriptions to a few weeks," lead author of the study and PhD student Sophie Billioti de Gage, PharmD, from the University of Bordeaux Segalen in France, told Medscape Medical News.

"In any case, uncontrolled use should be cautioned against," she said.

The study was published online September 27 in the British Medical Journal.

"Bad Drugs for Older Adults"

Greg A. Sachs, MD, who reviewed the study for Medscape Medical News, said it is "yet another study that suggests that benzodiazepines are bad drugs for older adults."

Dr. Sachs is chief of the Division of General Internal Medicine and Geriatrics, Indiana University School of Medicine, and investigator at the IU Center for Aging Research, Regenstrief Institute, Indianapolis. He was not involved in the study.

"Many of these drugs," Dr. Sachs said, "are on 'Do Not Prescribe' lists for older adults. If used at all, they should be used for short periods of time (10 days or less) and in the lowest dose possible to achieve benefit for the target symptom." Benzodiazepines "should not be used long term for either sleep or anxiety; safer alternatives exist."

The analysis included 1063 men and women (mean age, 78.2 years) from the PAQUID (Personnes Agées Quid) project, a prospective, population-based study of cognitive aging and dementia involving a total of 3777 participants from France. The study started in 1987 and follow-up lasted 20 years, with clinic visits every 2 to 3 years.

All participants in the current analysis were free of dementia at the outset and did not start taking benzodiazepines until at least the third year of follow-up. Ninety-five (8.9%) reported benzodiazepine use at the 5-year visit, indicating new use between years 3 and 5. Year 5 was baseline for the analysis.

During the 15-year follow-up period, 253 (23.8%) cases of dementia were confirmed: 30 (32%) in benzodiazepine users and 223 (23.0%) in nonusers.

The 15-year incidence rate of dementia per 100 person-years was higher in benzodiazepine users than nonusers (4.8 vs 3.2).

The multivariable adjusted hazard ratio (HR) for dementia with new use of benzodiazepines was 1.60 (95% confidence interval [CI], 1.08 - 2.38). This result was unchanged when further adjusted for depressive symptoms (HR, 1.62; 95% CI, 1.08 - 2.43).

The result "remained robust" in a secondary pooled analysis of patients who initiated a benzodiazepine between follow-up visits 8 and 15 (HR, 1.46; 95% CI, 1.10 - 1.94). This added a total of 116 additional new users during follow-up to the 95 new users at year 5.

Similarly, in a nested-case control study (467 case-patients with dementia and 1810 controls), the adjusted odds ratio (OR) with ever use vs never use was 1.55 (95% CI, 1.24 - 1.95). The results were similar in past users (OR, 1.56; 95% CI, 1.23 - 1.98) and recent users (OR, 1.48; 95% CI, 0.83 - 2.63).

The PAQUID investigators say their findings are consistent with 3 recent case-control studies that found an increased risk for dementia in benzodiazepine users.

Two of the studies from Taiwan (Wu et al, 2011Wu et al, 2009) used health insurance data and showed an increased risk for dementia in long-term users ( > 6 months; adjusted OR, 1.24; 95% CI, 1.01 - 1.53) and current users (adjusted OR, 2.71; 95% CI, 2.46 - 2.99).

The third study, a nested case-control study among French people, found an increased risk for dementia in former users (adjusted OR, 2.3; 95% CI, 1.2 - 4.5).

Other studies, however, have not found an increased risk for dementia among elderly people using benzodiazepines.

Dr. Billioti de Gage told Medscape Medical News that "contrary to most of the previous study on the topic, our study is based on a long period of follow-up (up to 15 years) and was carried out in a large representative cohort of elderly participants. This allows to take into account the somewhat long prodromal period of dementia and to generalize the conclusions."

"Positive Distinguishing Factors"

Dr. Sachs said there are several "positive distinguishing factors about this study." It was large; it followed patients over many years with little dropout; it was prospective and longitudinal rather than cross-sectional; the diagnosis of dementia involved both neuropsychological testing and examination by a neurologist; and the researches had excellent information about drug use from patients, he explained.

The exclusion of people who were already receiving benzodiazepines at time of study entry and for a period of a few years "run in" is another key strength, he said.

"This is important regarding the notion of 'reverse causation' — that people could end up taking benzodiazepines because of symptoms of depression or anxiety that are early symptoms relating to a developing dementia. Without doing that, it could bias the study toward people with dementia already brewing getting benzodiazepines at a higher rate, instead of the notion that it is contributing to dementia development," Dr. Sachs said.

The analyses were "carefully done" and the findings were "explored and confirmed using more than one approach. The PAQUID study is one of the higher quality cohort studies examining dementia," he added.

Dr. Billioti de Gage said, "patients should be told about the potential adverse effects of these drugs, including long-term risk when initiating benzodiazepines and about the necessity of gradual discontinuation when stopping the treatment."

She and her colleagues say further study is needed to determine whether long-term use of benzodiazepines in people younger than age 65 years is also associated with an increased risk for dementia and uncover possible correlations between dosage or cumulative length of exposure and dementia.

Dr. Sachs agrees. The analysis "cannot tell us anything about long versus short acting meds, specific meds, dose, or duration of therapy," he told Medscape Medical News. Also, the small numbers of people on benzodiazepines in the study is a limitation, he added.

Another limitation, he said, is that the analysis is primarily focused on "ever use" of benzodiazepines, "and that means we do not have information here on whether stopping the meds would help prevent dementia. In fact, because of the 'ever use' approach to analysis, I'd be concerned that someone misinterpret this and think 'why bother stopping' once someone has been exposed."

Dr. Sachs also noted that "far greater numbers of people who developed dementia had not been exposed to benzodiazepines than those who had; so while it increases relative risk, how much it contributes to development of dementia should not be overplayed; this still was an observational study, so assigning causation is hard to do no matter how well the study is done."

This research was conducted by the INSERM U657 research team co-funded by INSERM (Institut National de la Santé et de la Recherche Médicale) and Université Bordeaux Segalen. Additional support was provided by a 2010 grant from IRESP (Institut de Recherche en Santé Publique) acting on behalf of the French Ministry of Health (Direction Générale de la Santé, Direction de la Recherche, des Études, de l'Évaluation et des Statistiques); by a 2011 grant from the French Ministry of Health (Direction Générale de la Santé); and by Caisse Nationale des Travailleurs Salariés, Régime Social des Indépendants, Caisse Nationale de Solidarité pour l'Autonomie, and Institut National de Prévention et d'Education pour la Santé. SBdG is a part-time researcher in the INSERM 657 Unit, and her salary is paid by IRESP.

BMJ. Published online September 27, 2012. Abstract

Study Highlights

  • This prospective cohort study (PAQUID) enrolled 1063 men and women (mean age, 78.2 years) who were free of dementia and were not taking benzodiazepines until at least the third year of follow-up.
  • PAQUID assessed for normal and pathologic brain aging.
  • Follow-up visits were performed every 2 or 3 years.
  • Benzodiazepine use was assessed at each follow-up visit.
  • The main outcome measure was incidence of dementia, as confirmed by a neurologist.
  • During 15-year follow-up, 253 incident cases of dementia were confirmed: 30 (32%) in benzodiazepine users and 223 (23%) in nonusers.
  • Compared with nonusers at baseline, new use of benzodiazepines was associated with an increased risk for dementia (multivariable adjusted HR, 1.60; 95% CI, 1.08 - 2.38).
  • After adjustment for depressive symptoms, the results were similar (HR, 1.62; 95% CI, 1.08 - 2.43).
  • A secondary analysis pooled cohorts of participants who started benzodiazepines during follow-up and evaluated the association with incident dementia; the pooled HR across the 5 cohorts of new benzodiazepine users was 1.46 (95% CI, 1.10 - 1.94).
  • A complementary nested case-control study showed that any use of benzodiazepines was associated with an approximately 50% increase in the risk for dementia (adjusted OR, 1.55; 95% CI, 1.24 - 1.95) compared with no use.
  • Similar associations were found in past users (OR, 1.56; 95% CI, 1.23 - 1.98) and recent users (OR, 1.48; 95% CI, 0.83 - 2.63) but reached significance only for past users.
  • Limitations of this study included the following:
    • The small number of new users at baseline (n = 95) limited the power of subgroup analyses;
    • The investigators could not separately adjust for anxiety and sleep disorders; and
    • Possible selection bias due to the exclusion of people with missing information could have occurred.

Clinical Implications

  • Benzodiazepines are indicated for the short-term treatment of anxiety and sleep disorders.
  • New use of benzodiazepines was associated with an approximately 50% increased risk for dementia.

CME Test

  • Print